Inozyme Pharma INZY 深 沪
等待开盘 09-29 09:30:00 美东时间
4.00
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 4.00
- 总市值 2.58亿
- 52周最高 6.24
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.721
- 委 比 0.00%
- 总股本 6456.18万
- 历史最高 31.65
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.721
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
SCYNEXIS, Inc. announced the appointment of Sanjay Subramanian as Chief Financial Officer, effective September 9, 2026, succeeding Ivor Macleod, who is retiring. Subramanian brings over 20 years of experience in finance and business development across the biotech and pharmaceutical sectors. Macleod, who joined SCYNEXIS in 2022, will remain through October 9 to ensure a smooth transition. Subramanian was granted an option to purchase 100,000 share...
09-10 12:00
Inozyme Pharma Requests Nasdaq Delisting Post-Acquisition
An announcement from Inozyme Pharma ( ($INZY) ) is now available. Inozyme Pharm...
2025-07-01 21:48
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
Inozyme Pharma has postponed its 2025 Annual Meeting due to the pending acquisition by BioMarin Pharmaceutical Inc. If the acquisition is completed, the meeting will not be held. If not, the Board may reschedule it with a new record date. Inozyme, a biopharmaceutical company, focuses on bone health and blood vessel function, developing INZ-701 for ENPP1 Deficiency and other conditions.
2025-06-20 21:00
Inozyme Pharma Reports Increased Loss Amid Strategic Focus
Inozyme Pharma, Inc. ( ($INZY) ) has released its Q1 earnings. Here is a breakd...
2025-06-10 11:51
Inozyme Pharma Approves Executive Bonuses Amid Merger
Inozyme Pharma ( ($INZY) ) has issued an update. On May 16, 2025, Inozyme Pharm...
2025-06-02 19:58
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
2025-05-20 09:28
